Display options
Cite
Meng F, Khoso MH, Kang K, et al. FGF21 ameliorates hepatic fibrosis by multiple mechanisms. Mol Biol Rep. 2021;48(11):7153-7163doi: 10.1007/s11033-021-06707-0.
Meng, F., Khoso, M. H., Kang, K., He, Q., Cao, Y., Jiang, X., Xiao, W., & Li, D. (2021). FGF21 ameliorates hepatic fibrosis by multiple mechanisms. Molecular biology reports, 48(11), 7153-7163. https://doi.org/10.1007/s11033-021-06707-0
Meng, Fanrui, et al. "FGF21 ameliorates hepatic fibrosis by multiple mechanisms." Molecular biology reports vol. 48,11 (2021): 7153-7163. doi: https://doi.org/10.1007/s11033-021-06707-0
Meng F, Khoso MH, Kang K, He Q, Cao Y, Jiang X, Xiao W, Li D. FGF21 ameliorates hepatic fibrosis by multiple mechanisms. Mol Biol Rep. 2021 Nov;48(11):7153-7163. doi: 10.1007/s11033-021-06707-0. Epub 2021 Sep 18. PMID: 34536190.
Copy Download .nbib Format: NLM
Share it on

Mol Biol Rep. 2021 Nov;48(11):7153-7163. doi: 10.1007/s11033-021-06707-0. Epub 2021 Sep 18.

FGF21 ameliorates hepatic fibrosis by multiple mechanisms.

Molecular biology reports

Fanrui Meng, Mir Hassan Khoso, Kai Kang, Qi He, Yukai Cao, Xinghao Jiang, Wei Xiao, Deshan Li

Affiliations

  1. Northeast Agricultural University, Harbin, China.
  2. Department of Biochemistry, Shaheed Mohtarma Benazir Bhutto Medical University, Larkana, Pakistan.
  3. Jiangsu Kanion Pharmaceutical CO. LTD, Jiangsu, Lianyungang, State Key Laboratory of New-Tech for Chinese Medicine Pharmaceutical Process, Jiangsu, 220000, China. [email protected].
  4. Northeast Agricultural University, Harbin, China. [email protected].

PMID: 34536190 DOI: 10.1007/s11033-021-06707-0

Abstract

BACKGROUND: Previous study reports that fibroblast growth factor 21 (FGF21) could ameliorate hepatic fibrosis, but its mechanisms have not been fully investigated.

METHODS AND RESULTS: In this study, three models were used to investigate the mechanism by which FGF21 alleviates liver fibrosis. Hepatic fibrosis animal models were respectively induced by CCL

CONCLUSIONS: FGF21 ameliorates hepatic fibrosis by multiple mechanisms.

© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Keywords: FGF21; Liver fibrosis; SOCS3/leptin; TGF-β

References

  1. Kharitonenkov A, Adams AC (2014) Inventing new medicines: the FGF21 story. Mol Metab 3(3):221–229 - PubMed
  2. Nobuyuki, Itoh. FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases. Frontiers in Endocrinology. 5(2):p.152–159, (2014). - PubMed
  3. Dutchak PA, Katafuchi T, Bookout AL et al (2012) Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell 148:556–567 - PubMed
  4. Berglund ED, Li CY, Bina HA et al (2009) Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology. 150(9):4084–4093 - PubMed
  5. Lin Z, Pan X, Wu F et al (2015) Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. Circulation 131(21):1861–1871 - PubMed
  6. Li S, Zhu Z, Xue M et al (1865) (2019) Fibroblast growth factor 21 protects the heart from angiotensin II-induced cardiac hypertrophy and dysfunction via SIRT1. Biochimica et Biophysica Acta (BBA) 6:1241–1252 - PubMed
  7. Pan X, Shao Y, Wu F et al (2018) FGF21 Prevents angiotensin II-Induced hypertension and vascular dysfunction by activation of ACE2/angiotensin-(1–7) axis in mice. Cell Metab 27(6):1323–1337 - PubMed
  8. Lin X, Li G, He X et al (2014) FGF21 inhibits apolipoprotein(a) expression in HepG2 cells via the FGFR1-ERK1/2-Elk-1 pathway. Mol Cell Biochem 393(1–2):33–42 - PubMed
  9. Xu P, Zhang Y, Wang W et al (2015) Long-term administration of fibroblast growth factor 21 prevents chemically-induced hepatocarcinogenesis in mice. Digest Dis Sci 60:3032–3043 - PubMed
  10. Opoku YK et al (2020) Fibroblast growth factor-21 ameliorates hepatic encephalopathy by activating the stat3-socs3 pathway to inhibit activated hepatic stellate cells. EXCLJ J 19:567–581 - PubMed
  11. Xu P, Zhang Y, Wang W (2016) Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-β/smad2/3 and NF-κB signaling pathways. Toxicol Appl Pharmacol 290:43–53 - PubMed
  12. Lee KJ, Jang YO, Cha SK et al (2018) Expression of fibroblast growth factor 21 and β-klotho regulates hepatic fibrosis through the nuclear factor-κB and c-Jun N-terminal kinase pathways. Gut Liver 12(4):449–456 - PubMed
  13. Aydin MM, Akcali KC (2018) Liver fibrosis. Turk J Gastroenterol 29(1):14–21 - PubMed
  14. Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Investig 115(2):209–218 - PubMed
  15. Ramachandran P, Iredale JP (2012) Liver fibrosis: a bidirectional model of fibrogenesis and resolution. QJM 105(9):813–817 - PubMed
  16. Tsuchida T, Friedman SL (2017) Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol 14(7):397–411 - PubMed
  17. Zhang C et al (2016) Liver fibrosis and hepatic stellate cells: etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol 22(48):10512 - PubMed
  18. Saxena NK et al (2004) Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation. FASEB J 18(13):1612–1614 - PubMed
  19. Kouta I, Mrzljak A, Kolari B et al (2020) Leptin as a key player in insulin resistance of liver cirrhosis? A cross-sectional study in liver transplant candidates. J Clin Med 9(2):560 - PubMed
  20. Chen Z, Jain A, Liu H et al (2019) Targeted drug delivery to hepatic stellate cells for the treatment of liver fibrosis. J Pharmacol Exp Ther 370(3):695–702 - PubMed
  21. Yanguas SC, Cogliati B, Eillebrods J (2016) Experimental models of liver fibrosis. Arch Toxicol 90(5):1025–1048 - PubMed
  22. Scholten D, Trebicka J, Liedtke C et al (2015) The carbon tetrachloride model in mice. Lab Anim 49(1):4–11 - PubMed
  23. Korsrud GO, Harold C et al (1972) Sensitivity of several serum enzymes in detecting carbon tetrachloride-induced liver damage in rats. Toxicol Appl Pharmacol 22:474–483 - PubMed
  24. Verna L, Whysner J, Williams GM (1996) N-Nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Pharmacol Ther 71:57–81 - PubMed
  25. Liu X, Dai R, Ke M et al (2017) Differential proteomic analysis of dimethylnitrosamine (DMN)-induced liver fibrosis. Proteomics 17(22):1700267 - PubMed
  26. George J, Tsuchishima M, Tsutsumi M (2019) Molecular mechanisms in the pathogenesis of N-nitrosodimethylamine induced hepatic fibrosis. Cell Death Dis 10(1):52–59 - PubMed
  27. Van Dijk F et al (2015) Targeted therapies in liver fibrosis: combining the best parts of platelet-derived growth factor BB and interferon gamma. Front Med 2:257–260 - PubMed
  28. Friedman SL (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology 134(6):1655–1669 - PubMed
  29. Friedman SL, Yamasaki G, Wong L (1994) Modulation of transforming growth factor beta receptors of rat lipocytes during the hepatic wound healing response. J Biol Chem 269(14):10551–10558 - PubMed
  30. Borkham-Kamphorst E, Weiskirchen R (2016) The PDGF system and its antagonists in liver fibrosis. Cytokine Growth Factor Rev 28:53–61 - PubMed
  31. Bethanis SK, Theocharis SE (2006) Leptin in the field of hepatic fibrosis: a pivotal or an incidental player? Dig Dis Sci 51(10):1685–1696 - PubMed
  32. Kwon O, Kim KW, Kim M (2016) Leptin signaling pathways in hypothalamic neurons. Cell Mol Life Sci 73(7):1457–1477 - PubMed
  33. Sahin GS, Dhar M, Dillon C (2019) leptin stimulates synaptogenesis in hippocapal nerons via KLF4 and SOCS3 inhibition of STAT3 signaling. Mol Cell Neurosci 20:123–128 - PubMed
  34. Howard JK, Flier JS (2006) Attenuation of leptin and insulin signaling by SOCS proteins. Trends Endocrinol Metab 17(9):365–370 - PubMed
  35. Kim GY, Jeong H, Yoon H-M (2020) Anti-inflammatory mechanisms of suppressors of cytokine signaling target ROS via NRF-2/thioredoxin induction and inflammasome activation in macrophages. BMB Rep 53(12):640–645 - PubMed
  36. Zhang S et al (2018) FGF21 attenuates pulmonary fibrogenesis through ameliorating oxidative stress in vivo and in vitro. Biomed Pharmacother 103:1516–1525 - PubMed
  37. Jang JH, Kang KJ, Kim YH et al (2008) Reevaluation of experimental model of hepatic fibrosis induced by hepatotoxic drugs: an easy, applicable, and reproducible model. Transpl Proc 40(8):2700–2703 - PubMed
  38. Yang X, Lechleider RJ, Chen L et al (1999) Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J 18(5):1280–1291 - PubMed
  39. Trombley S, Maugars G, Kling P et al (2012) Effects of long-term restricted feeding on plasma leptin, hepatic leptin expression and leptin receptor expression in juvenile Atlantic salmon (Salmo salar L.). Gen Comp Endocrinol 175(3):92–99 - PubMed
  40. Otte C, Otte JM et al (2004) Expression of leptin and leptin receptor during the development of liver fibrosis and cirrhosis. Exp Clin Endocrinol Diabetes 112(01):10–17 - PubMed
  41. Foglia B, Cannito S, Bocca C et al (2019) ERK pathway in activated, myofibroblast-like, hepatic stellate cells: a critical signaling crossroad sustaining liver fibrosis. Int J Mol Sci 20(11):2700 - PubMed
  42. Lu C et al (2017) Nrf2 induces lipocyte phenotype via a SOCS3-dependent negative feedback loop on JAK2/STAT3 signaling in hepatic stellate cells. Int Immunopharmacol 49:203–211 - PubMed
  43. Gong Z, Lin J, Zheng J et al (2019) Dahuang Zhechong pill attenuates CCl - PubMed

Publication Types

Grant support